Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

CompletedOBSERVATIONAL
Enrollment

118

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

February 7, 2020

Study Completion Date

February 7, 2020

Conditions
Inflammatory Bowel Disease (IBD)Crohn's Disease (CD)Ulcerative Colitis (UC)
Interventions
DRUG

Inflectra

The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.

Trial Locations (15)

21045

Gastro Center of Maryland, Columbia

33135

Suncoast Research Group, LLC, Miami

44130

Paramount Medical Research & consulting, LLC, Middleburg Heights

45440

Dayton Gastroenterology, Inc., Beavercreek

46202

Indiana University Health Division of Gastroenterology/Hepatology, Indianapolis

49525

Infusion Associates N.E., Grand Rapids

58701

Trinity Health Center Medical Arts, Minot

60031

Illinois Gastroenterology Group, Gurnee

92120

San Diego Clinical Trials, San Diego

98664

The Vancouver Clinic Research, Vancouver

06518

Medical Research Center Of Connecticut, LLC, Hamden

T3H 0V5

Aspen Woods Clinic, Calgary

T5R 1W2

Brennan Walters Professional Corporation, Edmonton

V3L 3W5

Fraser Clinical Trials, New Westminster

H2V 2X1

Montreal IBD Center (CMIIM), Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY